0.02Open0.02Pre Close0 Volume10 Open Interest50.00Strike Price0.00Turnover101.85%IV38.29%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.0120Delta0.0062Gamma1808.50Leverage Ratio-0.0097Theta0.0001Rho21.75Eff Leverage0.0015Vega
Exelixis Stock Discussion
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed
No comment yet